NICE backs Pfizer’s Talzenna for adults with prostate cancer

23 January 2026

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today, the UK health technology assessor, National Institute for Health and Care Excellence announced today.

The NICE has recommended Talzenna (talazoparib), made by US pharma giant Pfizer (NYSE: PFE)), taken alongside enzalutamide, for adults with prostate cancer that has spread.

The treatment is recommended for people where chemotherapy is not suitable and who cannot tolerate or take abiraterone plus prednisolone, one of the current standard treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK